These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9741046)

  • 41. Dexfenfluramine.
    Goldstein DJ
    Nutrition; 1997 Jan; 13(1):51-2. PubMed ID: 9058451
    [No Abstract]   [Full Text] [Related]  

  • 42. Diet drugs and cardiac valvulopathy: a survey of dental patients.
    Rudin R; Carpenter W
    J Calif Dent Assoc; 2000 Dec; 28(12):955-9. PubMed ID: 11323951
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Psychiatric complications of amphetamine substances.
    Johnson J; Milner G
    Acta Psychiatr Scand; 1966; 42(3):252-63. PubMed ID: 5959089
    [No Abstract]   [Full Text] [Related]  

  • 44. [Residual states following schizophrenieform psychosis in epileptic patients (author's transl)].
    Kick H
    Nervenarzt; 1979 Sep; 50(9):596-600. PubMed ID: 119920
    [No Abstract]   [Full Text] [Related]  

  • 45. Nocturnal eating syndrome: a case report with therapeutic response to dexfenfluramine.
    Mancini MC; Alóe F
    Sao Paulo Med J; 1994; 112(2):569-71. PubMed ID: 7610330
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Eating related and general psychopathology in obese females with binge eating disorder.
    de Zwaan M; Mitchell JE; Seim HC; Specker SM; Pyle RL; Raymond NC; Crosby RB
    Int J Eat Disord; 1994 Jan; 15(1):43-52. PubMed ID: 8124326
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Obesity, dexfenfluramine, and pulmonary hypertension. A lesson not learned?
    Voelkel NF; Clarke WR; Higenbottam T
    Am J Respir Crit Care Med; 1997 Mar; 155(3):786-8. PubMed ID: 9117009
    [No Abstract]   [Full Text] [Related]  

  • 48. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
    Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE
    N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Severe mitral valve regurgitation associated with dexfenfluramine use.
    Aurigemma GP; Ronen A; Cuénoud H; Folland ED; Meyer TE
    Cardiology; 2002; 98(4):215-7. PubMed ID: 12566653
    [No Abstract]   [Full Text] [Related]  

  • 50. An open-label trial of sibutramine in obese patients with binge-eating disorder.
    Appolinario JC; Godoy-Matos A; Fontenelle LF; Carraro L; Cabral M; Vieira A; Coutinho W
    J Clin Psychiatry; 2002 Jan; 63(1):28-30. PubMed ID: 11838622
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modern medical management of obesity: the role of pharmaceutical intervention.
    Aronne LJ
    J Am Diet Assoc; 1998 Oct; 98(10 Suppl 2):S23-6. PubMed ID: 9787732
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Working memory predicts presence of auditory verbal hallucinations in schizophrenia and bipolar disorder with psychosis.
    Jenkins LM; Bodapati AS; Sharma RP; Rosen C
    J Clin Exp Neuropsychol; 2018 Feb; 40(1):84-94. PubMed ID: 28562181
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low vitamin D is associated with negative and depressive symptoms in psychotic disorders.
    Nerhus M; Berg AO; Kvitland LR; Dieset I; Hope S; Dahl SR; Weibell MA; Romm KL; Faerden A; Andreassen OA; Melle I
    Schizophr Res; 2016 Dec; 178(1-3):44-49. PubMed ID: 27595553
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recurrent overeating: an empirical comparison of binge eating disorder, bulimia nervosa, and obesity.
    Fichter MM; Quadflieg N; Brandl B
    Int J Eat Disord; 1993 Jul; 14(1):1-16. PubMed ID: 8339091
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial.
    Weissman NJ; Panza JA; Tighe JF; Gwynne JT
    Ann Intern Med; 2001 Feb; 134(4):267-73. PubMed ID: 11182836
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anorectic effect of dehydroepiandrosterone combined with dexfenfluramine or thionisoxetine.
    Rowland NE; Marshall M; Robertson K
    Eur J Pharmacol; 2001 May; 419(1):61-4. PubMed ID: 11348631
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In obese individuals dexfenfluramine corrects molecular derangements reflecting insulin resistance.
    Piccinini M; Rabbone I; Novi RF; Alberto G; Mostert M; Musso A; Vai S; Gamba S; Rinaudo MT
    Int J Obes Relat Metab Disord; 2000 Jun; 24(6):735-41. PubMed ID: 10878680
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour.
    Mathus-Vliegen EM; van de Voorde K; Kok AM; Res AM
    J Intern Med; 1992 Aug; 232(2):119-27. PubMed ID: 1506807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Psychotomimetic effects of anorectic drugs.
    Khan SA; Spiegel DA; Jobe PC
    Am Fam Physician; 1987 Aug; 36(2):107-12. PubMed ID: 3618447
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The temporal relationship between depressive and psychotic symptoms in recent-onset schizophrenia.
    Green MF; Nuechterlein KH; Ventura J; Mintz J
    Am J Psychiatry; 1990 Feb; 147(2):179-82. PubMed ID: 2301655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.